-$1.69 EPS Expected for 2seventy bio, Inc. (NASDAQ:TSVT) This Quarter

Posted by on Jun 6th, 2022

Wall Street brokerages predict that 2seventy bio, Inc. (NASDAQ:TSVT – Get Rating) will post ($1.69) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for 2seventy bio’s earnings, with the lowest EPS estimate coming in at ($2.01) and the highest estimate coming in at ($1.19). The business is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that 2seventy bio will report full-year earnings of ($8.90) per share for the current financial year, with EPS estimates ranging from ($9.18) to ($8.61). For the next year, analysts forecast that the firm will post earnings of ($5.13) per share, with EPS estimates ranging from ($6.87) to ($2.24). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow 2seventy bio.

2seventy bio (NASDAQ:TSVT – Get Rating) last posted its earnings results on Thursday, May 12th. The company reported ($3.20) EPS for the quarter, missing the consensus estimate of ($1.73) by ($1.47). The business had revenue of $8.43 million for the quarter, compared to the consensus estimate of $22.66 million. The firm’s quarterly revenue was down 29.2% on a year-over-year basis. During the same period last year, the company earned ($3.73) earnings per share.

A number of analysts have recently weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of 2seventy bio in a research note on Monday, May 2nd. They issued a “buy” rating and a $26.00 price objective for the company. Morgan Stanley reduced their price objective on shares of 2seventy bio to $31.00 and set an “overweight” rating for the company in a research note on Tuesday, May 17th. SVB Leerink assumed coverage on shares of 2seventy bio in a research note on Thursday, February 10th. They issued an “outperform” rating and a $38.00 price objective for the company. Finally, Zacks Investment Research cut shares of 2seventy bio from a “hold” rating to a “sell” rating in a research note on Wednesday, June 1st. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $32.83.

Institutional investors and hedge funds have recently bought and sold shares of the company. Royal Bank of Canada bought a new stake in 2seventy bio during the 1st quarter worth about $84,000. Group One Trading L.P. bought a new stake in 2seventy bio during the 1st quarter worth about $69,000. Ameritas Investment Partners Inc. bought a new stake in 2seventy bio during the 1st quarter worth about $30,000. Metropolitan Life Insurance Co NY bought a new stake in 2seventy bio during the 1st quarter worth about $25,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in 2seventy bio during the 1st quarter worth about $1,213,000. 50.43% of the stock is currently owned by institutional investors and hedge funds.

TSVT stock opened at $11.67 on Monday. 2seventy bio has a 12 month low of $10.57 and a 12 month high of $64.00. The firm has a 50 day moving average of $14.36 and a two-hundred day moving average of $18.83.

About 2seventy bio (Get Rating)

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma.

Featured Articles

Get a free copy of the Zacks research report on 2seventy bio (TSVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for 2seventy bio (NASDAQ:TSVT)

Want More Great Investing Ideas?

Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.